The effect of smoking cessation on quality of life after lung cancer surgery
…, P Sardari Nia, A Cogen, Y Dockx… - European journal of …, 2011 - academic.oup.com
Objective: This study aimed to evaluate the effect of smoking status on quality of life (QoL)
after non-small-cell lung cancer surgery with the European Organisation for Research and …
after non-small-cell lung cancer surgery with the European Organisation for Research and …
Neoadjuvant systemic therapy in breast cancer: Challenges and uncertainties
M Van de Wiel, Y Dockx, T Van den Wyngaert… - European Journal of …, 2017 - Elsevier
… Author links open overlay panel Mick Van de Wiel a 1 , Yanina Dockx a b 1 , Tim Van den
Wyngaert b c , Sigrid Stroobants b c , Wiebren AA Tjalma a , Manon T. Huizing a …
Wyngaert b c , Sigrid Stroobants b c , Wiebren AA Tjalma a , Manon T. Huizing a …
Efficacy Screening of Gloriosa Superba Extracts in a Murine Pancreatic Cancer Model Using 18F-FDG PET/CT for Monitoring Treatment Response
…, C Vangestel, A Wouters, Y Dockx… - Cancer Biotherapy …, 2016 - liebertpub.com
Purpose: In vivo efficacy of two herbal extracts of Gloriosa superba L. (Colchicaceae) was
investigated in a murine pancreatic tumor model by tumor volume measurements and Positron …
investigated in a murine pancreatic tumor model by tumor volume measurements and Positron …
18F-FDG and 18F-FLT Uptake Profiles for Breast Cancer Cell Lines Treated with Targeted PI3K/Akt/mTOR Therapies
Y Dockx, C Vangestel, S De Bruycker… - Cancer Biotherapy & …, 2023 - liebertpub.com
… Yanina Dockx … Yanina Dockx, Christel Vangestel, Sven De Bruycker, Tim Van den Wyngaert,
Manon Huizing, Steven Staelens, and Sigrid Stroobants.18F-FDG and 18F-FLT Uptake …
Manon Huizing, Steven Staelens, and Sigrid Stroobants.18F-FDG and 18F-FLT Uptake …
[HTML][HTML] Early changes in [18F] FDG uptake as a readout for PI3K/Akt/mTOR targeted drugs in HER-2-positive cancer xenografts
Y Dockx, C Vangestel, T Van den Wyngaert… - Molecular …, 2021 - hindawi.com
We investigated the potential use of [18F]FDG PET as a response biomarker for PI3K pathway
targeting therapies in two HER-2-overexpressing cancer models. Methods. CD-1 nude …
targeting therapies in two HER-2-overexpressing cancer models. Methods. CD-1 nude …
The predictive value of sentinel node biopsy in early breast cancer after neo-adjuvant chemotherapy: A prospective study
O Najim, Y Dockx, I Huyghe… - European Journal of …, 2018 - Elsevier
Objective A sentinel Node (SN) has replaced axillary lymph node dissection (ALND) in
patients with clinically node negative axilla (cN0). SN after Neo-adjuvant chemotherapy (NACT) …
patients with clinically node negative axilla (cN0). SN after Neo-adjuvant chemotherapy (NACT) …
Innovative molecular targeted agents in hepatocellular carcinoma: new gladiators on the arena
J Ferri, Y Dockx, L Vonghia… - … di chirurgia pratica …, 2017 - repository.uantwerpen.be
Abstract Treatment of advanced hepatocellular carcinoma remains a challenge, with
discouraging results in terms of survival. Following the approval of the multikinase inhibitor …
discouraging results in terms of survival. Following the approval of the multikinase inhibitor …
18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) as early imaging biomarker of axillary sentinel lymph node (SLN) status in locally advanced node …
Y Dockx, MT Huizing, T Van Den Wyngaert, S Altintas… - 2012 - ascopubs.org
1129 Background: Use of FDG-PET in the early evaluation of NACT for NPBC is currently
under investigation. The aim of this study is to assess FDG-PET in NPBC pts receiving NACT in …
under investigation. The aim of this study is to assess FDG-PET in NPBC pts receiving NACT in …
[PDF][PDF] Research Article Early Changes in [18 F] FDG Uptake as a Readout for PI3K/Akt/mTOR Targeted Drugs in HER-2-Positive Cancer Xenografts
Y Dockx, C Vangestel, T Van den Wyngaert, M Huizing… - 2021 - academia.edu
We investigated the potential use of [18F] FDG PET as a response biomarker for PI3K pathway
targeting therapies in two HER-2-overexpressing cancer models. Methods. CD-1 nude …
targeting therapies in two HER-2-overexpressing cancer models. Methods. CD-1 nude …
Not just a'usual'Li-Fraumeni syndrome
Y Dockx, A Goossen, J Decloedt… - Belgian Journal of …, 2020 - biblio.ugent.be
The Li-Fraumeni syndrome (LFS) is characterised clinically by the appearance of tumours in
multiple organs, generally at an early age. This hereditary condition is caused by germinal …
multiple organs, generally at an early age. This hereditary condition is caused by germinal …